FOCUS on Drug Approvals. The FDA has approved the first cancer drug based on discoveries from the Broad Institute of MIT and Harvard. Sevabertinib (BAY-2927088) was
FOCUS Biomolecules is a Philadelphia-based company, and we are celebrating the American Society for Cell Biology annual meeting in Philly! Visit us at ASCB booth #1424
FOCUS on New Drug Approvals. On November 13th the FDA announced approval of Ziftomenib (Komzifti, Kura Oncology), a menin inhibitor, for the treatment of adults with
FOCUS on Drug Repurposing. Moxidectin is an anthelmintic drug approved by the FDA in 2018 for onchocerciasis (river-blindness). It is a derivative of milbemycin, a structurally
FOCUS on New Drug Approvals. The FDA has approved Boehringer Ingelheim’s Nerandomilast (Jascayd, BI-101555) for patients with idiopathic pulmonary fibrosis (IPF) a rare, serious, and progressive
FOCUS on MS Drug Development. Roche announced this week that the first of two pivotal phase III studies (FENhance 1 and 2) in patients with relapsing
BOGO
